Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of “Buy” from Brokerages

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been assigned an average recommendation of “Buy” from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $18.75.

Several equities research analysts have recently weighed in on LXEO shares. Chardan Capital raised shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. decreased their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. Finally, Wall Street Zen lowered Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th.

Insider Buying and Selling

In related news, CEO Richard Townsend sold 25,947 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the sale, the chief executive officer directly owned 377,817 shares of the company’s stock, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the sale, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. This represents a 21.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 66,326 shares of company stock worth $299,817. 2.00% of the stock is currently owned by company insiders.

Institutional Trading of Lexeo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in shares of Lexeo Therapeutics by 6.1% in the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after buying an additional 1,626 shares during the period. California State Teachers Retirement System grew its position in shares of Lexeo Therapeutics by 123.7% during the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after buying an additional 2,148 shares during the last quarter. Intech Investment Management LLC raised its stake in Lexeo Therapeutics by 19.5% during the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after acquiring an additional 2,317 shares during the period. Allworth Financial LP raised its stake in Lexeo Therapeutics by 1,002.9% during the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after acquiring an additional 3,079 shares during the period. Finally, Susquehanna Portfolio Strategies LLC raised its stake in Lexeo Therapeutics by 14.4% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 26,205 shares of the company’s stock worth $260,000 after acquiring an additional 3,296 shares during the period. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Trading Up 1.3%

Shares of NASDAQ:LXEO opened at $4.84 on Friday. The company has a fifty day simple moving average of $4.73 and a 200 day simple moving average of $5.40. The firm has a market cap of $397.12 million, a PE ratio of -4.21 and a beta of 1.50. Lexeo Therapeutics has a 12-month low of $3.99 and a 12-month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.01). As a group, equities research analysts forecast that Lexeo Therapeutics will post -1.18 EPS for the current fiscal year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.